Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Gains from Investment Securities (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Gains from Investment Securities for 4 consecutive years, with $250000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities rose 941.67% year-over-year to $250000.0, compared with a TTM value of $226000.0 through Sep 2025, up 432.35%, and an annual FY2024 reading of $234143.0, down 45.39% over the prior year.
  • Gains from Investment Securities was $250000.0 for Q3 2025 at Atara Biotherapeutics, up from -$24000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $616000.0 in Q1 2022 and bottomed at -$597000.0 in Q2 2022.
  • Average Gains from Investment Securities over 4 years is $43166.7, with a median of $12500.0 recorded in 2023.
  • Peak annual rise in Gains from Investment Securities hit 22600.0% in 2024, while the deepest fall reached 344.09% in 2024.
  • Year by year, Gains from Investment Securities stood at -$357000.0 in 2022, then surged by 74.23% to -$92000.0 in 2023, then soared by 73.91% to -$24000.0 in 2024, then skyrocketed by 1141.67% to $250000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for ATRA at $250000.0 in Q3 2025, -$24000.0 in Q4 2024, and $24000.0 in Q3 2024.